Research on the clinical efficacy of lenalidomide combined with bortezomib and dexamethasone in treatment of multiple myeloma patients
来那度胺联合硼替佐米和地塞米松在多发性骨髓瘤患者治疗中的研究

摘要

目的 探究来那度胺联合硼替佐米和地塞米松方案用于多发性骨髓瘤病患治疗时呈现的临床效果并且分析该方案对病患生活质量产生的影响。方法 选择2024年1月到2024年12月我院收治46例多发性骨髓瘤患者作为案例，以随机数表法分为两组各23例。实验组采取来那度胺联合硼替佐米和地塞米松治疗，常规组采取硼替佐米联合地塞米松治疗，对比两组治疗有效率以及生活质量评分、不良反应发生率。结果 实验组治疗有效率、生活质量评分均高于常规组（P＜0.05），两组不良反应发生率比较无显著差异（P＞0.05）。结论 来那度胺联合硼替佐米和地塞米松方案治疗多发性骨髓瘤效果较好，能提升治疗有效率与病患生活质量，且安全性与常规方案相当，有着临床推广运用的价值。

Abstract

Objective To investigate the clinical efficacy of the regimen of lenalidomide combined with bortezomib and dexamethasone in the treatment of myeloma patients and analyze the impact of this regimen on the quality of life of patients.
Methods 46 cases of multiple myeloma patients admitted to our hospital from 2024 to December 2024 were selected as cases, and divided into two groups of 23 cases each by random number table method. The experimental was treated with lenalidomide combined with bortezomib and dexamethasone, and the control group was treated with bortezomib combined withamethasone. The treatment efficacy, quality of life scores and incidence of adverse reactions of the two groups were compared.
Results The treatment efficacy and quality of life scores of experimental group were higher than those of the control group (P < 0.05), and there was no significant difference in the incidence of adverse reactions between the two (P > 0.05).
Conclusion   The regimen of lenalidomide combined with bortezomib and dexamethasone is effective in treatment of multiple myeloma, can improve the treatment efficacy and the quality of life of patients, and its safety is comparable to that of conventional regimens, which has the value clinical promotion and application.